Loading...

XTL

XTLB

XTL BIOPHARMACEUTICALS LTD

(XTLB)

2026 6-K

ADS Ratio Change

20 Mar '26

Acquisition Update

10 Mar '26

Nasdaq Delisting Notice

27 Feb '26

Shareholder Meeting Results

24 Feb '26

Insolvency Proceedings

23 Feb '26

Extraordinary Meeting Update

17 Feb '26

Acquisition Update

28 Jan '26

Stockholder Equity Issue

23 Jan '26

Insolvency Filing

23 Jan '26

Meeting Notification

13 Jan '26

Acquisition Intent

13 Jan '26

Financial Results Update

30 Dec '25

Nasdaq Notification

29 Dec '25

Management Resignation

12 Dec '25

Management Change

5 Dec '25

Board Changes

23 Oct '25

Shareholder Meeting Results

28 Jul '25

Shareholder Meeting Postponed

21 Jul '25

Meeting Announcement

18 Jun '25

Shareholder Meeting Announc...

13 Jun '25

New CEO Appointment

7 Apr '25

Sublicense Agreement

4 Mar '25

Board Resignations

3 Feb '25

Financial Results Update

30 Dec '24

Acquisition Announcement

30 Dec '24

Settlement Agreement

19 Nov '24

Settlement Agreement

12 Nov '24

Acquisition Update

15 Oct '24

Acquisition Completed

14 Aug '24

Shareholder Meeting Results

22 Jul '24

Shareholder Meeting Notice

12 Jun '24

Share Purchase Agreement

5 Jun '24

Financial Update

13 May '24

Extraordinary Meeting Held

30 Apr '24

Regained Compliance

2 Apr '24

Extraordinary Meeting Notice

21 Mar '24

Extraordinary Meeting Notice

21 Mar '24

Business Acquisition Announced

20 Mar '24

External Links:

SEC

XTL Biopharmaceuticals Ltd.'s subsidiary, The Social Proxy, was ordered to begin insolvency proceedings and liquidation on February 22, 2026, due to insolvency, following a prior application's filing on January 23, 2026, affecting a $1.5 million loan extended by XTL.

AI Assistant

XTL BIOPHARMACEUTICALS LTD

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.